Knowledge Base

What is the difference between single-gene molecular diagnostic tests and ONCOMPASS™?

You probably already heard of the molecular diagnostic tests, which are intended to detect gene mutation linked to cancer. Detection of gene mutation (which also implies the identification of targets for existing drugs and drugs under development) will allow both you and your relatives to avail yourselves of modern targeted anticancer treatments.

Today several centers worldwide carry out molecular diagnostic tests, but only for certain genes or gene sequences. The best known tests are the KRAS test in colon cancer or the EGFR test in lung cancer and the HER-2 test in breast cancer. These tests allow predicting the efficiency or inefficacy of available targeted drugs already approved in the case of these cancers.

In the case of single-gene tests, the question is whether a targeted drug available in a particular oncology center can be administered to a particular patient. This is the so-called “patient to drug” approach.

In the case of multiple-gene tests first we determine the gene mutation present in the patient. After that we try to find out, using our molecular oncology databases, which targeted drug may be used for personalized administration in that oncology center or other oncology center in the world. This is the so-called “drug to patient” approach.

Oncompass entails not only a detailed multi gene molecular  test but also a full interpretation of the findings, and a list of potentially usefully clinical trials matching both the clinical and molecular profile of the patients.

Spread the word

Be social. Help others to stand up from cancer.
ONCOMPASS Gmbh.   |   Privacy Policy